Merk

KeyLynk-009

NCT04191135

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Status:

Recruiting

26459-200.png

II, III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

TNBC

Investigational

Product

Treatment Arms

o pembrolizumab + carboplatin and gemcitabine

o pembrolizumab + olaparib